Helsinn nominated as a Swiss Biotech Success Story 2019/2020 by the Swiss Biotech Association
May 07, 2019 11:19 ET
|
Helsinn Healthcare S.A.
Helsinn nominated as a Swiss Biotech Success Story 2019/2020 by the Swiss Biotech Association Switzerland, May 7, 2019: Helsinn, a Swiss pharmaceutical group focused on building quality cancer care...
Winners of the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced
March 19, 2019 18:00 ET
|
Helsinn Healthcare S.A.
Winners of the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced Mihir Shah of UE LifeSciences Inc. has been selected as the winner of the 2019 Lyfebulb-Helsinn...
Helsinn initiates two new global Phase III studies with anamorelin
March 07, 2019 03:00 ET
|
Helsinn Healthcare S.A.
Helsinn initiates two new global Phase III studies with anamorelin Helsinn committed to anamorelin which is being evaluated for weight loss and anorexia in patients with advanced non small cell lung...
Helsinn Investment Fund: Ten finalists have been chosen for the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology
February 27, 2019 08:15 ET
|
Helsinn Healthcare S.A.
Ten finalists have been chosen for the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology The Award recognizes Patient Entrepreneurs’ innovations for cancer and cancer...
Helsinn Investment Fund Invests €1 Million in Gain Therapeutics
February 19, 2019 02:30 ET
|
Helsinn Healthcare S.A.
Helsinn Investment Fund Invests €1 Million in Gain Therapeutics Luxembourg, February 19, 2019: Helsinn Investment Fund S.A, SICAR, a fund focused on early-stage investment opportunities in areas of...
Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in Blood Advances
February 14, 2019 15:22 ET
|
Helsinn Healthcare S.A.
Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in the Frontline Treatment of Older AML Patients Unfit for Intensive Chemotherapy, in Blood...
Helsinn Provides Educational Grant for ESMO’s Preceptorship for Supportive and Palliative Care
January 31, 2019 03:00 ET
|
Helsinn Healthcare S.A.
Helsinn Provides Educational Grant for ESMO’s Preceptorship for Supportive and Palliative Care Lugano, Switzerland, January 31, 2019 – Helsinn, a Swiss pharmaceutical group focused on...
Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US
January 02, 2019 08:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US Akynzeo® for injection received a permanent J code, J1454, in the US, by the...
Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat
December 21, 2018 08:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat Licensing rights are worldwide excluding US, Canada, Japan and South America Lugano, Switzerland and Florence, Italy,...
RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA®
December 20, 2018 07:00 ET
|
Helsinn Healthcare S.A.
RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA® Milan and Lugano, December 20, 2018 – Recordati and Helsinn announce the signing of a license agreement between...